News | Hypertension | June 04, 2019

BackBeat Cardiac Neuromodulation Therapy Shows Immediate, Substantial Blood Pressure Reduction

Data showed 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at three months and 23.4 mmHg reduction in office cuff systolic blood pressure out to two years

BackBeat Cardiac Neuromodulation Therapy Shows Immediate, Substantial Blood Pressure Reduction

June 4, 2019 — Orchestra BioMed Inc. announced the presentation of two-year clinical data from the European Moderato I study of BackBeat Cardiac Neuromodulation Therapy (“BackBeat CNT”) for hypertension at the EuroPCR Conference, May 21-24 in Paris, France. Prof. Petr Neužil, M.D., Ph.D., CSc., FESC, head of the department of cardiology of Na Homolce Hospital in Prague, Czech Republic, presented data which showed a strong safety profile of BackBeat CNT and its ability to immediately, substantially and chronically lower blood pressure in patients with persistent hypertension (office BP > 150 mmHg) despite two or more anti-hypertensive medications and an indication for a pacemaker.

"In the Moderato I study, BackBeat CNT demonstrated an impressive 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at three months as well as a substantial and sustained 23.4 mmHg reduction in office cuff systolic blood pressure out to two years. These statistically significant results are very exciting as they support the potential for BackBeat CNT to become a broadly applicable therapy for device-based hypertension management,” said Neužil, one of the principal investigators of the study.

BackBeat CNT is applicable to a wide range of hypertensive patients, including isolated systolic disease and patients with high blood pressure despite medical therapy. The Moderato I study enrolled patients with uncontrolled hypertension despite multi-drug medical management and who are also indicated for a pacemaker.

“We are encouraged by the data from Moderato I study showing substantial reduction in systolic blood pressure which could potentially reduce the risk of heart attack and stroke,” said Darren R. Sherman, president, chief operating officer and founder of Orchestra BioMed. “We recently completed enrollment of patients in the Moderato II study to further investigate the efficacy and safety of BackBeat CNT for the treatment of hypertension and are on track to present 6-month data later this year.”

Orchestra BioMed recently completed enrollment in the Moderato II study. The study is a prospective, 1:1 randomized double-blind active treatment with BackBeat CNT versus standard medical therapy trial in pacemaker-indicated patients with uncontrolled blood pressure and treated with at least one antihypertensive medication. The primary efficacy and safety endpoints will be assessed at six months.

“We are looking forward to Moderato II six-months results and the long-term potential of this exciting therapy to benefit high-risk patients with uncontrolled high blood pressure,” stated Neužil.

In 2019, Orchestra BioMed plans to initiate enrollment in a randomized, double-blind study to assess the clinical safety and effectiveness of BackBeat CNT in patients with hypertension in the absence of antihypertensive medications. The primary efficacy endpoint will be the difference in the average 24-hour ambulatory systolic blood pressure in the active group compared to control at three months after randomization.

Read the article "BackBeat Cardiac Neuromodulation Therapy Reduces Blood Pressure at Two Years"

For more information: www.orchestrabiomed.com

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init